Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Tech medical study

GLP-1 Drugs Linked to Wernicke Encephalopathy

Analysis based on 6 articles · First reported Sep 11, 2026 · Last updated Sep 15, 2026

Sentiment
-15
Attention
4
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The study raises safety concerns around the two dominant GLP-1 franchises, which could weigh on sentiment for Novo Nordisk and Eli Lilly shares if regulators or prescribers react, though the small number of cases and the study's inability to establish causation limit the immediate market effect. Broader GLP-1 demand is unlikely to be derailed, but headlines about rare serious side effects may add volatility to the obesity-drug sector.

pharmaceuticals healthcare

A study published in Clinical Nutrition identified 15 reported cases of Wernicke encephalopathy, a rare and potentially life-threatening neurological disorder caused by severe vitamin B1 (thiamine) deficiency, in patients taking GLP-1 receptor agonists. Most cases involved semaglutide, marketed as Ozempic, Wegovy and Rybelsus by Novo Nordisk, or tirzepatide, sold as Mounjaro and Zepbound by Eli Lilly and Company. Researchers identified the cases through the United States — Food and Drug Administration's Adverse Event Reporting System (FAERS), published medical literature and their own medical center. Many patients experienced gastrointestinal or nutritional issues including weight loss, vomiting, loss of appetite and malnutrition, which can contribute to thiamine deficiency. Reports of the disorder appeared disproportionately among GLP-1 users compared with patients on other drugs, though researchers cautioned the study cannot prove the medications caused the condition. Experts including clinician Karthik Achari and nutritionist Erin Palinski-Wade stressed the findings should be viewed in perspective given millions of patients use these drugs, and advised patients not to stop prescribed GLP-1 medications based on the findings alone. The study authors called for additional research. Fox News Digital reached out to Novo Nordisk, Eli Lilly and the researchers for comment.

40 United States — Food and Drug Administration collected adverse event reports
stock
Maker of semaglutide-based Ozempic, Wegovy and Rybelsus, the drugs most frequently linked to the reported Wernicke encephalopathy cases. The negative safety headline could pressure its shares and invite regulatory scrutiny, though causation is unproven.
Importance 85.0 Sentiment -25.0
stock
Maker of tirzepatide-based Mounjaro and Zepbound, which accounted for six of the reported cases. The association adds a safety concern to its fast-growing GLP-1 franchise, a potential headwind for sentiment.
Importance 80.0 Sentiment -20.0
govactor
Its Adverse Event Reporting System supplied 13 of the 15 cases reviewed, placing the agency at the center of any potential label or safety review of GLP-1 medications.
Importance 45.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.